Quest Diagnostics Incorporated (NYSE:DGX) is scheduled to be releasing its earnings data before the market opens on Thursday, October 19th. Analysts expect Quest Diagnostics to post earnings of $1.43 per share for the quarter. Quest Diagnostics has set its FY17 guidance at $5.62-5.72 EPS.

Quest Diagnostics (NYSE:DGX) last posted its earnings results on Tuesday, July 25th. The medical research company reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.13. Quest Diagnostics had a return on equity of 15.66% and a net margin of 9.28%. The company had revenue of $1.94 billion for the quarter, compared to analyst estimates of $1.94 billion. During the same quarter in the previous year, the firm earned $1.34 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. On average, analysts expect Quest Diagnostics to post $5.66 EPS for the current fiscal year and $5.86 EPS for the next fiscal year.

Quest Diagnostics Incorporated (NYSE:DGX) opened at 91.45 on Thursday. Quest Diagnostics Incorporated has a 1-year low of $79.12 and a 1-year high of $112.96. The stock has a market cap of $12.47 billion, a price-to-earnings ratio of 18.43 and a beta of 0.65. The firm has a 50-day moving average price of $101.06 and a 200 day moving average price of $104.89.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 18th. Shareholders of record on Tuesday, October 3rd will be given a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 1.97%. The ex-dividend date of this dividend is Monday, October 2nd. Quest Diagnostics’s dividend payout ratio is currently 36.29%.

COPYRIGHT VIOLATION NOTICE: “Quest Diagnostics Incorporated (DGX) Set to Announce Earnings on Thursday” was first posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/12/quest-diagnostics-incorporated-dgx-set-to-announce-earnings-on-thursday.html.

In related news, Chairman Stephen H. Rusckowski sold 59,235 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total transaction of $6,406,857.60. Following the transaction, the chairman now owns 220,049 shares in the company, valued at approximately $23,800,499.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Daniel Stanzione sold 40,900 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $108.07, for a total value of $4,420,063.00. Following the transaction, the director now owns 41,991 shares in the company, valued at approximately $4,537,967.37. The disclosure for this sale can be found here. Insiders have sold a total of 161,996 shares of company stock worth $17,517,207 in the last 90 days. 1.75% of the stock is currently owned by company insiders.

A number of equities research analysts have issued reports on the company. UBS AG increased their price target on Quest Diagnostics from $115.00 to $123.00 and gave the company a “buy” rating in a research report on Thursday, July 6th. BidaskClub raised Quest Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th. Zacks Investment Research lowered Quest Diagnostics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. ValuEngine lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Finally, Morgan Stanley increased their price target on Quest Diagnostics from $87.00 to $92.00 and gave the company an “underweight” rating in a research report on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $110.41.

About Quest Diagnostics

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).

Earnings History for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.